After studying Molecular and Cellular Biology at the University Heidelberg, Germany and the University of Bergen, Norway, I obtained my Ph.D. from the EMBL and the Combined Faculty of Natural Sciences and Mathematics of the University of Heidelberg for work on primary cell culture development and tissue patterning based on phase-encoding using molecular oscillators.
In 2014, I moved to Karolinska Institutet as a MarieCurie fellow to work on the development and characterization of physiological hepatic model systems and became Assistant Professor and group leader in Liver function and Regeneration with Emphasis on Drug Development in 2017. My research is focused on physiological and pathophysiological hepatic in vitro models for drug toxicity, mechanisms underlying hepatic plasticity and regeneration and on the genetic basis of drug response.
The commercialization of relevant discoveries constitutes one of the key aims of EU’s Horizon 2020 program and I am very enthusiastic about making innovations available to the public. To this end, we founded HepaPredict AB, providing 3D hepatic model systems for hepatotoxicity testing, pharmacokinetic applications and mechanistic studies of drug candidates to the pharmaceutical industry.
Since 2017: Assistant Professor in Liver Function and Regeneration with Emphasis on Drug Development (Karolinska Institutet, Stockholm, Sweden)
2014 - 2016: Postdoctoral Research Associate and MarieCurie Fellow (Karolinska Institutet, Stockholm, Sweden)
2012 – 2016: Bachelor of Science in Business Administration and Economics (University of Hagen, Germany)
2013 – 2014: Bridging Postdoctoral Research Associate (EMBL Heidelberg, Germany)
2009 – 2013: Dr. rer. nat. / PhD studies (EMBL Heidelberg, Germany)
2007 – 2009: Scientific Assistant in Molecular Genomics and Evolution (University of Heidelberg, Germany)
2007 – 2009: Master of Science in Molecular Biosciences (University of Heidelberg, Germany)
2004 – 2007: Bachelor of Science in Molecular and Cellular Biology (University of Heidelberg, Germany and University of Bergen, Norway)
My research interests are focused on liver metabolism and function as well as hepatic pathologies. We previously established an integrated 3D spheroid cell culture system for primary human hepatocytes (PHH) in which cells remain viable and functionally stable for multiple weeks. Importantly, we recently showed that PHH in this model exhibited superior sensitivity to hepatotoxic agents compared to other emerging cell models, such as HepG2 and HepaRG cells, and were faithfully reproducing in vivo drug toxicity mechanisms in man. Furthermore, using a combination of untargeted and targeted metabolomics, we showed that the endogenous and xenobiotic metabolic signatures of PHH were maintained in 3D spheroids, thus allowing to comprehensively study drug-induced molecular effects on cellular metabolism and to investigate mechanisms of drug action. The results indicate that the 3D PHH spheroid system faithfully mimics heptic phenotypes in vivo and can be utilized for long-term analyses of drug metabolism, liver function and regulation.
In vitro toxicity models.
We aim to establish the spheroid model as a platform for the prediction of drug-induced liver injury (DILI) using a large panel of compounds that are hepatotoxic in man. Integration of histological, transcriptomic and metabolomic signatures during different stages of DILI will allow in-depth analyses of toxicity mechanisms. Matching these toxicity profiles to the suggested mechanisms of toxicity observed in vivo, will systematically reveal which molecular frameworks that underlie hepatic toxicity can be recapitulated using the 3D culture system in vitro. Furthermore, these studies facilitate the elucidation of biomarkers and yet unknown mechanisms of toxicity that can guide future in vivo studies and can aid targeted compound optimization to prevent toxicity while retaining biological activity.
Development of hepatic disease models.
Non-alcoholic fatty liver disease (NAFLD) constitutes a clinicopathological condition that accounts for the majority of chronic liver disease cases in the Western world. Onset of NAFLD is hallmarked by the accumulation of lipids within hepatocytes (hepatic steatosis), which arises from an imbalance between triglyceride import, production and extrusion primarily caused by obesity and a hypercaloric diet. In some patients steatosis can progress to non-alcoholic steatohepatitis (NASH), an inflammatory condition that can further develop in liver fibrosis. Despite its significant importance, no pathophysiologically replicative model systems exist. Based on our 3D primary human hepatocyte spheroid model, we aim to develop and extensively characterize a novel in vitro platform that is suitable to study liver biology during steatosis, NASH and fibrosis, as well as to screen compounds either for steatotic side effects or for anti-steatotic action.
Hepatic spheroids as model system for liver regeneration.
Strikingly, during spheroid aggregation stages, PHH first dedifferentiate, followed by rapid redifferentiation, providing an ideal ex vivo experimental paradigm to study the full spectrum of differentiation state changes that occur in vivo during liver regeneration. Besides extending our mechanistic understanding, this finding opened possibilities for the development of therapeutic approaches as a substitute for orthotopic liver transplantations. To this end, we work on the establishment of protocols in which PHH isolated from patients proliferate and, after cells sufficiently multiplied, are induced to redifferentiate into functional hepatocytes using our 3D spheroid culture system. We recently showed that miRNAs are important driving forces in the hepatic dedifferentiation process; knowledge which, besides being of mechanistic importance, can be useful for the optimization of hepatic redifferentiation.
Evaluation of the importance of rare genetic variants on hepatic metabolism and drug response.
Genetic variants primarily in drug and metabolite transporters, phase I and phase II drug metabolizing enzymes and nuclear receptors can influence drug response by modulating drug absorption, distribution, metabolism and excretion (ADME). Importantly, while in the past decades an ever-growing arsenal of genetic variants with demonstrated impacts on human drug response has been identified in these pharmacogenes, a substantial fraction of the heritable variability in drug response remains unexplained. Rare genetic variants that only occur in very few individuals and are hence missed in genome-wide association studies have been proposed to contribute to this missing heritability. We integrate data from recent population-wide Next-Generation Sequencing (NGS) projects to quantify the extent of genetic variability in pharmacogenes on a population level and, using an arsenal of in silico techniques, quantify the impact on hepatic metabolism and pharmacokinetics and -dynamics.
At KI I teach courses in local anaesthetics, cardiovascular pharmacology, pharmacokinetics and receptor pharmacology.
MSc projects are available upon request.
Akademiska priser och utmärkelser
2017 Lennart Philipson Prize
2016 VR Starting Grant
2016 VR 3R Grant
2016 KI Fonder Grant
2016 VR Proof-of-concept Grant (Co-applicant)
2016 KI Early Verification Grant
2015 Lars Hierta Research Grant
2015 Sigurd och Elsa Goljes Minne Research Grant
2015 Eva och Oscar Ahréns Grant for Medical Research
2014 Marie Curie Fellowship
2013 Dedicated Research Highlight article in Nature Reviews Genetics
2013 Dedicated News and Views article in Nature
2009 EMBL International PhD Program Graduate Fellowship
2009 Top Master of Science (M.Sc.) Award
2006 Erasmus Fellowship